Objective: To increase the safety and effectiveness of treatments for overactive bladder (OAB) with moderate symptoms in elderly patients. Patients and Methods: Patients were examined at the Urodynamic Department of the Regional Diagnostic Center (Vladivostok, Russian Federation) from September 1, 2012 to December 31, 2012. The assignment of patients [n = 177, average age 69. 4 years, 98 women (55.4%) and 79 men (44.6%)] was random and blind in this placebo-controlled study. Patients were distributed into subgroups according to the method of treatment as follows: group А1: n = 57, trospium 30 mg/day + solifenacin 10 mg/day; group А2: n = 61, trospium 15 mg/day + solifenacin 5 mg/day; group А3: n = 59, placebo. All patients underwent a urodynamic examination in accordance with international standards before and 2 months after treatment. ICIQ-SF questionnaires recommended by the International Continence Society (ICS) and bladder diaries were used to evaluate the clinical results. The clinical severity of the OAB symptoms and the effectiveness of the treatment were evaluated based on the frequency of episodes of incontinence (EI) per day. Three or fewer EI per day were considered moderate dysfunction of the lower urinary tract. Results: Groups of elderly patients with moderate symptoms of OAB who were treated with standard- and low-dose trospium and solifenacin demonstrated a significant increase in the median values of reflex volume, bladder capacity, and detrusor compliance and a decrease in the frequency of urination and urinary urgencies. The frequency of EI in both of the main groups decreased by almost 2-fold in comparison to the initial data and reached the following values: group А1: 1.27 (-1.08), p ≤ 0.05; group A2: 1.49 (-1.18), p ≤ 0.05. The correlation with the decrease in the frequency of EI in these groups was r = 0.85 (p ≤ 0.01). The percentage of patients with a significant decrease (EI ≥1.0) among those treated with standard- and low-dose trospium and solifenacin increased synchronously, prompting us to suppose the absence of a direct correlation between medicine dose and therapeutic effect for moderate OAB symptoms. Conclusion: The combination of low-dose trospium and solifenacin provides good clinical and urodynamic effects in elderly patients with moderate symptoms of OAB. Combination of these drugs in standard doses for such patients is excessive.

1.
Bschleipfer T, Wagenlehner FM, Lüdecke G, et al: Overactive bladder in the elderly. Urologe A 2013;52:800-804.
2.
Diamond P, Hassonah S, Lovatsis D, et al: The prevalence of detrusor overactivity amongst patients with symptoms of overactive bladder: a retrospective cohort study. Int Urogynecol J 2012;23:1577-1580.
3.
Patrick DL, Khalaf KM, Dmochowski R, et al: Psychometric performance of the incontinence quality-of-life questionnaire among patients with overactive bladder and urinary incontinence. Clin Ther 2013;35:836-845.
4.
Kurita N, Yamazaki S, Fukumori N, et al: Overactive bladder symptom severity is associated with falls in community-dwelling adults: LOHAS study. BMJ Open 2013;3: e002413.
5.
Natalin R, Lorenzetti F, Dambros M: Management of OAB in those over age 65. Curr Urol Rep 2013;14:379-385.
6.
Wagg A: Treating overactive bladder in the elderly. Can Urol Assoc J 2011;5(suppl 2): S149-S151.
7.
Gupta K, Kaushal S: Medical treatment of overactive bladder: an overview. Curr Clin Pharmacol 2012;7:229-239.
8.
Murphy AM, Krlin RM, Goldman HB: Treatment of overactive bladder: what is on the horizon? Int Urogynecol J 2013;24:5-13.
9.
Andersson KE: New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxin A. Ther Clin Risk Manag 2013;9:161-170.
10.
Igawa Y, Aizawa N, Homma Y: Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol 2010; 51:811-818.
11.
Kosilov K, Loparev S, et al: Management of overactive bladder (OAB) in elderly men and women with combined, high-dosed antimuscarinics without increased side effects. UroToday Int J 2013;6:art 47.
12.
Kosilov K, Loparev S, et al: Elderly men with overactive bladder: maintenance of satisfactory therapeutic effect of administration of combined high-dosed antimuscarinics. UroToday Int J 2013;6:art 67.
13.
Kosilov K, Loparev S, et al: Maintenance of the therapeutic effect of two high-dosage antimuscarinics in the management of overactive bladder in elderly women. Int Neurourol J 2013;17:1-6.
14.
Singh G, Lucas M, Dolan L, Knight S, Ramage C, Hobson PT: Minimum standards for urodynamic practice in the UK. Neurol Urodyn 2010;29:1365-1372.
15.
Gomes CM, Arap S, Trigo-Rocha FE: Voiding dysfunction and urodynamic abnormalities in elderly patients. Rev Hosp Clin Fac Med Sao Paulo 2004;59:206-215.
16.
Tissot W, Amundsen CL, Diokno AC, Webster GD, Coats AC: Bladder diary measurements in asymptomatic males: frequency, volume per void, and 24-hour volume. Neurourol Urodyn 2008;27:198-204.
17.
Dmochowski R, Larson-Peters A, Aronstein W, et al: Efficacy of darifenacin in patients with varying baseline symptom severity. UroToday Int J 2009;2(3).
18.
Burger M, Betz D, Hampel C, et al: Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study. World J Urol 2014;32:1041-1047.
19.
Oefelein MG, Tong W, Kerr S, et al: Effect of concomitant administration of trospium chloride extended release on the steady-state pharmacokinetics of metformin in healthy adults. Clin Drug Investig 2013;33:123-131.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.